{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:10:52Z","timestamp":1793110252010,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001797","name":"Pharmaceutical Research and Manufacturers of America Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030821","name":"College of Pharmacy, Health Science Center, University of Tennessee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030821","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG040146"],"award-info":[{"award-number":["R01AG040146"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.japh.2023.12.023","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T18:56:06Z","timestamp":1704308166000},"page":"463-470.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effects of medication therapy management on medication utilization among Medicare beneficiaries with HIV\/AIDS"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-2590","authenticated-orcid":false,"given":"Xiangjun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3929-6227","authenticated-orcid":false,"given":"Junling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2023.12.023_bib2","author":"Dawson"},{"issue":"8","key":"10.1016\/j.japh.2023.12.023_bib3","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","author":"Trickey","year":"2017","journal-title":"Lancet HIV"},{"issue":"10","key":"10.1016\/j.japh.2023.12.023_bib4","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/QAD.0000000000002963","article-title":"Assessing comorbidities and survival in HIV-infected and uninfected matched Medicare enrollees","volume":"35","author":"Yu","year":"2021","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.japh.2023.12.023_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241833","article-title":"Assessing the health status and mortality of older people over 65 with HIV","volume":"15","author":"Turrini","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.japh.2023.12.023_bib6","first-page":"1","article-title":"Ageing with HIV: Medicine Optimisation challenges and support needs for older people living with HIV: a systematic review","author":"Sarma","year":"2023","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.japh.2023.12.023_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0000000000001741","article-title":"The association of chronic pain and long-term opioid therapy with HIV treatment outcomes","volume":"79","author":"Merlin","year":"2018","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.japh.2023.12.023_bib8","article-title":"Pain in people living with HIV\/AIDS: a systematic review","volume":"17","author":"Parker","year":"2014","journal-title":"J\u00a0Int AIDS Soc"},{"issue":"1","key":"10.1016\/j.japh.2023.12.023_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/AJP.0b013e3182201a0f","article-title":"Prescription long-term opioid use in HIV-infected patients","volume":"28","author":"Silverberg","year":"2012","journal-title":"Clin J Pain"},{"issue":"5","key":"10.1016\/j.japh.2023.12.023_bib10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/QAI.0000000000002183","article-title":"Benzodiazepine use is associated with an increased risk of neurocognitive impairment in people living with HIV","volume":"82","author":"Saloner","year":"2019","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.japh.2023.12.023_bib11","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis","volume":"356","author":"Sun","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.japh.2023.12.023_bib12","first-page":"85","article-title":"Cohort study of the impact of high-dose opioid analgesics on overdose mortality","volume":"17","author":"Dasgupta","year":"2016","journal-title":"Pain Med"},{"issue":"5","key":"10.1016\/j.japh.2023.12.023_bib13","first-page":"243","article-title":"Evolution of the Medicare Part D medication therapy management program from inception in 2006 to the present","volume":"12","author":"Gray","year":"2019","journal-title":"Am Health Drug Benefits"},{"issue":"6","key":"10.1016\/j.japh.2023.12.023_bib16","first-page":"688","article-title":"Comparison of medication therapy management services and their effects on health care utilization and medication adherence","volume":"25","author":"Ferries","year":"2019","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"5","key":"10.1016\/j.japh.2023.12.023_bib17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jval.2022.09.2480","article-title":"Cost-effectiveness of medication therapy management program across racial and ethnic groups among Medicare beneficiaries","volume":"26","author":"Tsang","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.japh.2023.12.023_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-022-07483-8","article-title":"Effects of Medicare comprehensive medication review on racial\/ethnic disparities in nonadherence to statin medications among patients with Alzheimer\u2019s disease: an observational analysis","volume":"22","author":"Browning","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.japh.2023.12.023_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/2137284","article-title":"Revisiting the behavioral model and access to medical care: does it matter?","author":"Andersen","year":"1995","journal-title":"J\u00a0Health Soc Behav"},{"issue":"2","key":"10.1016\/j.japh.2023.12.023_bib25","first-page":"142","article-title":"Characteristics of older adults who meet the annual prescription drug expenditure threshold for medicare medication therapy management programs","volume":"13","author":"Daniel","year":"2007","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"6","key":"10.1016\/j.japh.2023.12.023_bib26","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A\u00a0comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.japh.2023.12.023_bib28","series-title":"Technical Specifications for PQA-Endorsed Measures, 2018","year":"2018"},{"issue":"9","key":"10.1016\/j.japh.2023.12.023_bib29","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1080\/03007995.2021.1935224","article-title":"Effects of the Medicare Part D comprehensive medication review on medication adherence among patients with Alzheimer\u2019s disease","volume":"37","author":"Dong","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.japh.2023.12.023_bib30","first-page":"212","article-title":"A\u00a0population-based Approach to improving patient safety related to drug-drug interactions","volume":"7","author":"Hines","year":"2015","journal-title":"Am J Pharm Benefits"},{"key":"10.1016\/j.japh.2023.12.023_bib32","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/QAD.0b013e32835584ea","article-title":"Antiretroviral therapy adherence and drug\u2013drug interactions in the aging HIV population","volume":"26","author":"Nachega","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.japh.2023.12.023_bib33","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1007\/s11606-013-2449-6","article-title":"Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population","volume":"28","author":"Holtzman","year":"2013","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.japh.2023.12.023_bib34","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1007\/s10461-016-1325-x","article-title":"Correlates of combination antiretroviral adherence among recently diagnosed older HIV-infected adults between 50 and 64 years","volume":"20","author":"Abara","year":"2016","journal-title":"AIDS Behav"},{"issue":"Suppl 1","key":"10.1016\/j.japh.2023.12.023_bib35","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/00002030-200418001-00004","article-title":"Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse","volume":"18","author":"Hinkin","year":"2004","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.japh.2023.12.023_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/jgs.12695","article-title":"Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection","volume":"62","author":"Greene","year":"2014","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"9","key":"10.1016\/j.japh.2023.12.023_bib37","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1377\/hlthaff.2016.0258","article-title":"Eligibility for and enrollment in Medicare Part D medication therapy management programs varies by plan sponsor","volume":"35","author":"Stuart","year":"2016","journal-title":"Health Aff"},{"key":"10.1016\/j.japh.2023.12.023_bib39","author":"Fan"},{"issue":"12","key":"10.1016\/j.japh.2023.12.023_bib40","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/gerona\/gly283","article-title":"Coprescribing of benzodiazepines and opioids in older adults: rates, correlates, and national trends","volume":"74","author":"Rhee","year":"2019","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"10.1016\/j.japh.2023.12.023_bib41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2318-11-35","article-title":"Primary care providers' perspective on prescribing opioids to older adults with chronic non-cancer pain: a qualitative study","volume":"11","author":"Spitz","year":"2011","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.japh.2023.12.023_bib42","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11904-011-0098-0","article-title":"Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011","volume":"8","author":"Puskas","year":"2011","journal-title":"Curr HIV AIDS Rep"},{"issue":"4","key":"10.1016\/j.japh.2023.12.023_bib43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/YCO.0000000000000337","article-title":"Gender differences in prescription opioid use","volume":"30","author":"Serdarevic","year":"2017","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"10.1016\/j.japh.2023.12.023_bib44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/QAI.0b013e3181845589","article-title":"Discrimination, distrust, and racial\/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients","volume":"49","author":"Thrasher","year":"2008","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.japh.2023.12.023_bib45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s11606-017-4199-3","article-title":"Cultural issues in medication adherence: disparities and directions","volume":"33","author":"McQuaid","year":"2018","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.japh.2023.12.023_bib46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pmedr.2017.12.010","article-title":"Outpatient, combined use of opioid and benzodiazepine medications in the United States, 1993\u20132014","volume":"9","author":"Hirschtritt","year":"2018","journal-title":"Prev Med Rep"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123004351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123004351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:53:48Z","timestamp":1761544428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319123004351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1544319123004351"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2023.12.023","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of medication therapy management on medication utilization among Medicare beneficiaries with HIV\/AIDS","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2023.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}